Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.
Cultural competence vs safety – related, but different
A culturally competent practitioner knows about the beliefs and behaviours of patients from different cultures, and has the skill to apply this knowledge to healthcare delivery.
Read the HAH Bulletin to find out more.
Careful writing and editing, and an equity lens, have been instrumental in updating the type 2 diabetes HealthPathways, helping to reduce unnecessary variation in treatment plans and outcomes.
Compliance, adherence, concordance – confused?
Whatever terminology is used, studies show that differences in health literacy, medicines access, attitudes to health and prescriber perceptions, may contribute to sub-optimal use of medicines and poor health outcomes.1
Read the HAH Bulletin to find out about strategies to improve medicine access/supply.
When clinically indicated, empagliflozin can be started in patients with type 2 diabetes using the steps shown in this resource.
Talking points, relevant for all patients starting empagliflozin, are provided along with two algorithms and accompanying prescribing notes. Which algorithm you follow will depend on your patient’s level of hypoglycaemia risk.
Focusing on the experiences of older Māori in primary care, this course comprises four short videos, an independent reflection, downloadable posters and additional resources.
The course is endorsed by RNZCGP and CNA(NZ) and meets PCNZ recertification requirements. Reflection templates are included for you to complete.
This Quality Improvement Activity enables you to review the glycaemic management of your type 2 diabetes patients and identify those who may benefit from initiation or intensification of blood glucose lowering medicines.
Good glycaemic control has a clear benefit on microvascular outcomes and if started early enough, on long-term macrovascular outcomes of coronary artery disease, stroke and peripheral vascular disease.
This is a Measuring and Improving Outcomes (MIO) activity that meets RNZCGP CPD requirements.
Diabetes clinical nurse specialist Lisa Sparks discusses the place of empagliflozin and dulaglutide in treatment of type 2 diabetes, with emphasis on potential side effects, sick-day management and improving patient adherence.
Māori attitudes to healthcare today are deeply rooted in New Zealand history. In this article, Deborah Bassett-Clarke discusses some reasons why the current model of pharmacy practice does not always meet the needs of Māori and may actually cause health inequities. Understanding these factors is an important first step to improving outcomes for Māori.
Medicine affordability is one of the five drivers of medicine access equity.
Up to 40 per cent of people continue to pay prescription copayments even though they are entitled to an exemption.1 No person or family should pay more than $100 per annum for subsidised medicines.
Read the HAH bulletin to find out more.
This list of Q&A reflects issues discussed in webinars held early in 2021.
The content has been edited, and reviewed by Waikato DHB endocrinologist/diabetologist Dr Ryan Paul.
Your patient uses gliclazide and insulin but could still benefit from the additional cardiovascular and renal protections of empagliflozin. How would you manage the change in treatment?
This case study is particularly relevant to prescribers. It originally appeared in the 3 March 2021 issue of New Zealand Doctor Rata Aotearoa and has been republished with permission.
Current management of type 2 diabetes includes two new classes of medication, SGLT2 inhibitors and GLP-1 receptor agonists, where clinically indicated. This article was published in the April 2021 edition of Kai Tiaki. It has been edited specifically for our nursing readership from an article that appeared in New Zealand Doctor and Pharmacy Today late in 2020.
This article is endorsed by the College of Nurses Aotearoa (NZ) Inc.